See more : Source Rock Royalties Ltd. (SRR.V) Income Statement Analysis – Financial Results
Complete financial analysis of Qualigen Therapeutics, Inc. (QLGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Qualigen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- American Noble Gas, Inc. (IFNY) Income Statement Analysis – Financial Results
- Dowway Holdings Limited (8403.HK) Income Statement Analysis – Financial Results
- Unicon Optical Co., Ltd. (4150.TWO) Income Statement Analysis – Financial Results
- GMR Airports Infrastructure Limited (GMRINFRA.NS) Income Statement Analysis – Financial Results
- Ningbo Solartron Technology Co.,Ltd. (688299.SS) Income Statement Analysis – Financial Results
Qualigen Therapeutics, Inc. (QLGN)
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.20M | 4.98M | 5.65M | 4.31M | 5.56M | 5.80M | 9.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.21M | 4.30M | 4.33M | 7.19M | 3.98M | 5.42M | 7.90M | 18.45M | 8.91M | 3.48K | 2.14K | 758.00 |
| Gross Profit | -4.50K | 680.80K | 1.32M | -2.88M | 1.58M | 378.39K | 1.87M | -18.45M | -8.91M | -3.48K | -2.14K | -758.00 |
| Gross Profit Ratio | -0.09% | 13.66% | 23.37% | -66.87% | 28.43% | 6.52% | 19.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.21M | 6.84M | 11.72M | 3.55M | 1.21M | 1.32M | 2.87M | 13.29M | 2.26M | 113.93K | 461.55K | 1.39M |
| General & Administrative | 6.10M | 10.84M | 11.72M | 8.02M | 1.51M | 1.05M | 4.78M | 4.88M | 6.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -4.50K | 950.42K | 542.59K | 400.17K | 367.95K | 380.34K | 618.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.09M | 11.79M | 12.27M | 8.42M | 1.88M | 1.43M | 4.78M | 4.88M | 6.40M | 2.16M | 1.65M | 2.01M |
| Other Expenses | -5.21M | 1.13K | 5.45K | 0.00 | 2.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.10M | 18.62M | 23.98M | 17.40M | 3.08M | 1.42M | 7.65M | 18.17M | 8.66M | 2.28M | 2.11M | 3.40M |
| Cost & Expenses | 11.30M | 22.93M | 28.32M | 24.59M | 7.06M | 6.85M | 15.55M | 36.62M | 17.57M | 2.28M | 2.11M | 3.40M |
| Interest Income | 0.00 | 26.65K | 42.69K | 138.80K | 123.05B | 152.04K | 40.23K | 60.88K | 40.88K | 525.00 | 1.68K | 2.91K |
| Interest Expense | 1.52M | 26.65K | 0.00 | 0.00 | 283.10K | 0.00 | 0.00 | 0.00 | 0.00 | 213.52K | 6.08K | 54.64K |
| Depreciation & Amortization | 4.50K | 12.17K | 322.06K | 138.65K | 111.38K | 5.70K | 5.70K | 5.21K | 1.94K | 3.48K | 2.14K | 758.00 |
| EBITDA | -11.30M | -13.84M | -22.66M | -11.16M | -10.02M | -717.86K | -7.86M | -18.38M | -8.79M | -2.26M | -2.09M | -3.40M |
| EBITDA Ratio | -217.12% | -285.64% | -478.41% | -259.27% | -23.10% | -12.37% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.30M | -17.94M | -22.66M | -11.30M | -1.50M | -1.06M | -15.55M | -36.62M | -17.57M | -2.28M | -2.11M | -3.40M |
| Operating Income Ratio | -217.20% | -360.03% | -400.85% | -262.49% | -27.05% | -18.18% | -159.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.17M | 872.81K | 4.77M | -7.74M | 711.17K | -140.55K | 38.60K | 18.24M | 8.79M | -191.85K | 14.97K | -51.73K |
| Income Before Tax | -12.48M | -21.30M | -17.89M | -20.42M | -1.78M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Income Before Tax Ratio | -239.78% | -427.40% | -316.46% | -474.18% | -32.09% | -20.61% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -4.79K | -265.07K | 5.43K | 619.00 | 4.00K | 4.62K | 5.09K | -5.21K | -1.94K | 1.00 | 0.00 | 0.00 |
| Net Income | -13.42M | -21.03M | -17.90M | -20.42M | -1.79M | -1.20M | -7.86M | -18.38M | -9.18M | -2.47M | -2.10M | -3.45M |
| Net Income Ratio | -257.79% | -422.08% | -316.55% | -474.16% | -32.16% | -20.69% | -80.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| EPS Diluted | -2.46 | -5.48 | -6.10 | -28.21 | -2.85 | -2.26 | -14.04 | -20.44 | -31.15 | -794.00 | -42.42K | -61.12K |
| Weighted Avg Shares Out | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
| Weighted Avg Shares Out (Dil) | 5.07M | 3.84M | 2.93M | 723.72K | 627.00K | 530.47K | 560.22K | 899.33K | 294.68K | 3.12K | 62.30 | 62.30 |
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials
Source: https://incomestatements.info
Category: Stock Reports